AI Article Synopsis
- Advances in asthma management have led to improved control and increased use of inhaled corticosteroids, showing a positive trend in treatment from 1998 to 2008.
- Despite these improvements, certain conditions remain unchanged, and there has been no decrease in emergency asthma-related deaths.
- Future efforts must focus on addressing these lingering issues in asthma management to enhance patient outcomes.
Article Abstract
Background: Despite the advances of asthma management and the accompanying improved asthma control, many problems related to asthma management still remain. The Niigata Asthma Treatment Study Group has been regularly collecting information via surveys since 1998 using a questionnaire, on problems related to asthma management; various studies on asthma management have been reported using data from the questionnaire.
Methods: The aim of this study was to investigate the changes in asthma control and management for every two-year period using the data from 1998 to 2008; future problems requiring resolution were extracted and discussed.
Results: The number of cases surveyed each year was about 3,000 (2,593-3,347 cases). The changes in the data from 1998 to 2008, including asthma attacks and symptoms rate, indicated the improvement of asthma control with the spread of medication according to the guidelines; of particular note, there was a 24.1% increase in the usage rate of inhaled corticosteroids during the study period. From 2002 to 2008, however, some asthmatic conditions seemed to show no improvement with regards to asthma control related to the rates of changes in peak flow meter use, leukotriene receptor antagonist use and oral sustained-released theophylline use. Moreover, there was no decrease in the occurrence of emergency episodes related to asthma deaths.
Conclusion: In the actual clinical setting, asthma control seems to be progressing well with the appropriate changes of medication according to the guidelines, and in part due to inhaled corticosteroid use. However, there were two problems which need to be addressed: 1) no improvement in some asthmatic conditions and 2) the occurrence of emergency episodes related to asthma deaths. In the future, it will be necessary to manage asthma in view of these points.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2169/internalmedicine.51.6586 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Copy Number Variation in Asthma: An Integrative Review.
Clin Rev Allergy Immunol
January 2025
Postgraduate Program in Biochemistry, Federal University of Espírito Santo (UFES), Vitória, Espírito Santo, Brazil.
Asthma is a complex disease with varied clinical manifestations resulting from the interaction between environmental and genetic factors. While chronic airway inflammation and hyperresponsiveness are central features, the etiology of asthma is multifaceted, leading to a diversity of phenotypes and endotypes. Although most research into the genetics of asthma focused on the analysis of single nucleotide polymorphisms (SNPs), studies highlight the importance of structural variations, such as copy number variations (CNVs), in the inheritance of complex characteristics, but their role has not yet been fully elucidated in asthma.
View Article and Find Full Text PDFEffect of dupilumab on otitis media associated with eosinophilic chronic rhinosinusitis.
Braz J Otorhinolaryngol
January 2025
Tokushima University Graduate School, Institute of Biomedical Sciences, Department of Otolaryngology-Head and Neck Surgery, Tokushima, Japan.
Objective: Eosinophilic Otitis Media (EOM) is an intractable disease caused by type 2 inflammation, such as Eosinophilic Chronic Rhinosinusitis (ECRS) and bronchial asthma. Biologics have recently been used to treat ECRS and bronchial asthma. Biologics are not indicated for EOM; however, because approximately 10% of ECRS cases has concomitant EOM, concomitant EOM improvement has been observed when dupilumab is administered for ECRS.
View Article and Find Full Text PDFThe relationship between MUC5AC levels in lung and asthma: a meta-analysis based on animal experiments.
J Asthma
January 2025
Department of Occupational and Environmental Health, School of Public Health, Jilin University, Changchun, China.
Introduction: Asthma is one of the severe respiratory diseases and affects the health of people globally. Animal studies have found that the mucin 5ac（Muc5ac） levels in the lung are associated with asthma. This paper aimed to systematically evaluate the relationship between Muc5ac levels in lung and asthma by extracting relevant data from animal experiments.
View Article and Find Full Text PDFAmbulatory blood pressure profiles of children with asthma compared to healthy controls.
Pediatr Nephrol
January 2025
Pediatric Nephrology, Faculty of Medicine, Ankara City Hospital, Ankara Yıldırım Beyazıt University Ankara, Bilkent, Turkey.
Background: Studies suggest that asthma and hypertension may be comorbid conditions. Most of these studies are epidemiological research. However, data on the relationship between asthma and hypertension in childhood are limited.
View Article and Find Full Text PDFAssociation between chronic respiratory diseases and frailty in Chinese elderly: a population-based longitudinal study.
BMJ Open Respir Res
January 2025
Peking University, Beijing, China
Background: Chronic respiratory diseases (CRDs) have been shown to be associated with frailty, but these findings have not yet reached a consensus. The aim of this study was to investigate the association between CRDs and frailty in the elderly using a nationally representative data from China.
Methods: Data from the China Health and Retirement Longitudinal Study (CHARLS) were analysed, including 3309 frailty-free participants followed for three waves from 2011.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!